Pharos I Bio and K-Medi Hub to Jointly Develop AI-Based Anticancer Drugs

Joint Research Agreement on EGFR-Targeted Anticancer Drugs
Combining AI Drug Design and Structural Biology
Strengthening PHI-701 Development and Resistance-Overcoming Strategies

Pharos I Bio announced on July 24 that it has signed a memorandum of understanding (MOU) for joint research on AI-based new drug development with K-Medi Hub (Daegu-Gyeongbuk Medical Innovation Foundation).

From the left, Junghyuk Yoon, CEO of Pharos I-Bio, and Guseon Park, Chairman of K-MediHub, are taking a commemorative photo after signing a 'Joint Research Agreement for AI-Based New Drug Development.' Pharos I-Bio

The two organizations will combine Pharos I Bio's AI drug design technology with K-Medi Hub's expertise in structural biology research to jointly develop next-generation EGFR-targeted anticancer drugs. They will collaborate on research including protein structure identification, structure-based drug design (SBDD), and optimization of candidate substances.

Pharos I Bio will use its proprietary AI drug discovery platform 'Chemiverse' to design candidate substances, while K-Medi Hub will support structure analysis and validation. The plan is to enhance research and development efficiency by integrating AI-based drug design with structural biology.

The research results obtained through this collaboration will also be applied to the development of EGFR-targeted anticancer drug candidate PHI-701 and other EGFR pipeline projects. Pharos I Bio aims to accelerate the development of next-generation oncology drugs that overcome resistance to existing EGFR therapies.

Junghyuk Yoon, CEO of Pharos I Bio, stated, "We will strengthen collaboration with external specialized institutions to further enhance our research and development outcomes and the potential for commercialization, leveraging our accumulated AI-driven drug development expertise."

This content was produced with the assistance of AI translation services.